Alcohol Septal Ablation
Treatment for Hypertrophic Cardiomyopathy
Effectiveness
80%
Safety Score
48%
Clinical Trials
8
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
48
DangerousModerateSafe
Treatment Details
Time to Effect
Immediate obstruction reduction, full symptomatic improvement over weeks to months
Treatment Duration
One-time procedure, lifetime benefit
Evidence Quality
MODERATE-HIGHNumber Needed to Harm (NNH)
7(Treat 7 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$100
Monitoring:$500
Side Effect Mgmt:$1,000
Total Annual:$1,600
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$90,000/QALY
QALYs Gained
7
Outcome-Based Costs
Cost per Responder
$2,000
Comparison vs Surgical Septal Myectomy
Cost Difference
$-20,000/year
Less expensive
QALY Difference
-1.00 QALYs
Worse outcomes
Dominance
No dominance
Alcohol Septal Ablation Outcomes
for Hypertrophic Cardiomyopathy
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+80%
Common Side Effects
Complete heart block requiring pacemaker
+15%
Arrhythmias (AFib, VT)
+10%
Pericardial effusion
+5%
Transient chest pain
+30%
Death
+0.8%
Active Clinical Trials
2 active trials recruiting for Alcohol Septal Ablation in Hypertrophic Cardiomyopathy
Surgical Septal Myectomy vs Percutaneous Transluminal Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy
NCT04684290RECRUITINGNA
100 participants
INTERVENTIONAL
Nieuwegein, Netherlands
Started: Jun 30, 2021
Echocardiography-guided Percutaneous Septal Radiofrequency Ablation for Obstructive HCM After Alcohol Septal Ablation
NCT06496633ACTIVE NOT RECRUITING
12 participants
OBSERVATIONAL
Xi'an, China
Started: Mar 26, 2024
Completed Clinical Trials
4 completed trials for Alcohol Septal Ablation in Hypertrophic Cardiomyopathy
The Effect of TASH in Patients With HOCM
NCT04066777COMPLETEDNA
24 participants
INTERVENTIONAL
Aarhus N, Denmark
Started: May 29, 2019
Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study
NCT00035386COMPLETEDPHASE2
12 participants
INTERVENTIONAL
Bethesda, United States
Started: Apr 1, 2002
A Comparison of Two Treatments: Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic Cardiomyopathy
NCT00001894COMPLETEDPHASE2
70 participants
INTERVENTIONAL
Bethesda, United States
Started: Aug 1, 1999
Effect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic Cardiomyopathy
NCT04133532COMPLETEDPHASE4
22 participants
INTERVENTIONAL
Prague, Czechia
Started: Mar 5, 2020